Pfizer hopes he can advise on biosimilars.
Scott Gottlieb served as FDA Commissioner for two years, recently retiring from the post in April 2019. During his tenure, he pushed through policies enabling the FDA to reduce the time for biosimilar approvals, as well as many others.
Now the ex-FDA head has joined the board of directors of Pfizer, one of the largest drug manufacturers in the world. Pfizer is hoping Gottlieb can provide advice on how to get its biosimilar through the approval process more quickly.
Said Pfizer Executive Chairman and former CEO Ian Read: “Scott’s expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives.” Gottlieb is currently a resident fellow at the American Enterprise Institute and a special partner at venture capital firm New Enterprise Associates.